Predictors of characteristics associated with negative SARS-CoV-2 PCR test despite proven disease and association with treatment and outcomes.

The COVID-19 RT-PCR Study.

Jean-Baptiste Lascarrou, MD, PhD[1,2*]; Gwenhael Colin, MD[2,3]; Aurélie Le Thuaut, MSc[4]; Nicolas Serck, MD[5]; Mickael Ohana, MD[6]; Bertrand Sauneuf, MD[7]; Guillaume Geri, MD[8]; Jean-Baptiste Mesland, MD[9]; Gaetane Ribeyre, MD[10]; Claire Hussenet, MD[11]; Anne Sophie Boureau, MD[12]; Thomas Gille, MD[13]

1. Medecine Intensive Reanimation, University Hospital Centre, Nantes, France
2. CRICS-TRIGGERSEP Network, Tours, France
3. Medecine Intensive Reanimation, District Hospital Centre, La Roche-sur-Yon, France
4. Plateforme de Méthodologie et Biostatistique, CHU Nantes, 1 places Alexis Ricordeau, 44093 Nantes Cedex 9, France
5. Unité de soins intensifs, Clinique Saint Pierre, Ottignies, Belgium
6. Service de radiologie, CHRU Strasbourg, Strasbourg, France
7. Réanimation - Médecine Intensive, Centre Hospitalier Public du Cotentin, BP208, 50102 Cherbourg-en-Cotentin, France
8. Médecine Intensive Réanimation, CHU Ambroise Paré, Boulogne Billancourt, France
9. Unité de soins intensifs, Hopital de Jolimont, Jolimont, Belgium
10. Centre médical, Avignon, France
11. Médecine Polyvalente, Nouvelles Cliniques Nantaises, Nantes, France
12. Médecine Aigue Gériatrique, CHU Nantes, Nantes, France
13. Pneumologie, University Hospital Center Avicenne, Bobigny, France

CORRESPONDING AUTHOR

Jean-Baptiste Lascarrou**,** Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hotel-Dieu, 30 Bd. Jean Monnet, 44093 Nantes Cedex 1, FRANCE

Phone: + 33 240 087 365

E-mail: jeanbaptiste.lascarrou@chu-nantes.fr

FUNDING

Funded solely.

CONFLICTS OF INTEREST

Authors have any conflict of interest to declare.

AUTHORS CONTRIBUTION

JBL was responsible for the study concept and design;

All authors: acquisition of the data;

JBL, GC, NS, MO, BS, GG, JBM, GR, CH, ASB, TG: analysis and interpretation of the data;

DG and JBL, NS, GG, ASB, TG: drafting of the manuscript;

ALT: perform statistical analysis;

All authors: critical revision of the manuscript for important intellectual content.

All authors read and approved the final manuscript.

The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

ABSTRACT

Background:

Since December 2019, Coronavirus 2019 (Covid-19) emerged in Wuhan city in China, and rapidly spread throughout China, Asia and worldwide. Recently, concerns emerged about specificity of PCR testing especially sensibility. We hypothesis first that clinical and/or biological and/or radiological characteristics of patients with first false negative COVID-19 RT-PCR test despite final diagnosis of COVID-19 are different from patients with first positive COVID-19 RT-PCR test.

Methods:

Case – control study in which patients with first negative COVID-19 RT-PCR test were matched to patients with first positive COVID-19 RT-PCR test on age, gender and ward/ICU location at time of RT-PCR test.

Results:

Between March 30, and June 22, 2020, 82 cases and 80 controls were included. Neither proportion of death at hospital discharge, nor duration of hospital length stay differed between patients "Cases" and "Controls" (respectively P=0.53 and P=0.79). In multivariable analysis, fatigue and/or malaise (aOR: 0.16 [0.03 ; 0.81]; P=0.0266), headache (aOR: 0.07 [0.01 ; 0.49]; P=0.0066) were associated with lower risk of false negative whereas platelets upper than 207 per $10.^{3}.mm^{-3}$ (aOR: 3.81 [1.10 ; 13.16]; P=0.0344), and CRP>79.8 $mg.L^{-1}$ (aOR: 4.00 [1.21 ; 13.19]; P=0.0226) were associated with higher risk of false negative.

Interpretation:

Patients suspected of COVID-19 with higher inflammatory biological findings expected higher risk of false negative COVID-19 RT-PCR test. Strategy of serial RT-PCR test must be rigorously evaluated before adoption by clinicians.

INTRODUCTION

Since December 2019, Coronavirus 2019 (COVID-19) emerged in Wuhan city in China, and rapidly spread throughout China, Asia and worldwide (1). On September 1, 2020 more than 25 000 000 patients has been infected and 850 000 died.

Coronaviruses are enveloped RNA viruses that are distributed broadly among humans, other mammals, and birds and that cause respiratory, enteric, hepatic, and neurologic diseases. Identification and sequencing of COVID-19 has been performed by Chinese team with rapid communication of their results in order to test suspected patients with reverse transcriptase polymerase chain reaction (RT-PCR) testing (2). Increasing literature has emerged to highlight multiple presentations of COVID-19 even though respiratory symptoms are predominant (3). In front of presence of multiple nonspecific symptoms, accurate diagnosis is the first cornerstone of health care with possible implications for isolation, corticosteroids administration, and location of hospitalization (ward / intensive care unit).

Recently, concerns emerged about performance of RT-PCR test especially sensibility as highlighted by report of 2 false negative COVID-19 RT-PCR test by Li et al (4). In a cohort of 219 patients COVID-19 confirmed match to 205 patients with respiratory failure from other virus than COVID-19, Bai *et al* (5) found than chest CT scan outperformed nasopharyngeal test to rule in or rule out Covid-19 disease. While the analytic performance of COVID-19 RT-PCR tests are well described (6), clinical performance can be diminished by several factors: low levels of shedding (7), variability in the site of acquisition (8) and technical background of nurses, technicians in charge of RT-PCR testing. Whereas

symptoms of COVID-19 infection are not specific: fever, cough, fatigue and lymphopenia (1), RT-PCR testing and interpretation of results can be a concern for clinicians.

We hypothesis first that clinical and/or biological and/or radiological characteristics of patients with first false negative COVID-19 RT-PCR test despite final diagnosis of COVID-19 are different from patients with first positive COVID-19 RT-PCR test; second that patients with first false negative COVID-19 RT-PCR expected better outcome than patients with first positive COVID-19 RT-PCR test. To answer this, we performed a case-control study in which patients with first negative COVID-19 RT-PCR test were matched to patients with first positive COVID-19 RT-PCR test.

METHODS

Design

We performed a multicenter retrospective analysis of patients admitted in hospital for suspicion of COVID-19 infection and negative COVID-19 RT-PCR (case) with control: patients hospitalized in the same hospital match on gender, age and ward / intensive care unit (ICU) service with first positive COVID-19 RT-PCR test.

Definition of case and control

Cases were patients with first negative RT-PCR test despite final diagnosis of COVID-19 leading to hospital admission.

Controls were patients with first positive RT-PCR test matched on age, gender and ward/ICU in the same hospital.

Eligibility

Inclusion criteria were:

- Age > 18 years
- Covid19 infection confirmed
    - Negative Covid19 RT-PCR for case
    - Positive Covid19 RT-PCR for control

Non-inclusion criteria were:

- Biological identification of other virus responsible of respiratory diseases
- Pregnancy, recent delivery or lactation
- Adult under guardianship, curatorship

Outcomes

Our primary objective was to identify factors associated with higher risk of false negative first COVID-19 RT-PCR test (regarding sensibility of RT-PCR testing). Secondary outcomes were treatments delivered, need for mechanical ventilation, duration of mechanical ventilation, occurrence of acute respiratory syndrome and outcome at hospital discharge.

Data collected

All data in the eCase Report Form were anonymized, and no data can be traced back to the patient's identity. Each local investigator filled an eCRF to collect data (Castor EDC, Amsterdam, The Netherlands). Data collected were: characteristics of matching: age, gender, location; baseline demographics (comorbidities); clinical and biological characteristics at hospital admission; history of symptoms; radiological findings; RT-PCR testing results (first and final RT-PCR test if positive for “case” patient); other pathogens testing and result; antiviral treatments; outcomes; modalities of final diagnosis for “case” patient.

Ethics

The study was approved by the appropriate ethics committees (For France: *Comité d’éthique de la Société de Réanimation de Langue Française*, #20-26; and for Belgium: *Comité d’Ethique 045 Clinique Saint Pierre*) which waived consent according to data collected.

Statistical analysis

Statistical analysis were performed according to STROBE guidelines (9). Cases were matched with controls on age, gender, and location of hospital admission (ward/intensive care unit) on 1:1 basis. Qualitative variables were described as n (%) and quantitative variables as mean±SD if normally distributed and median [25th-75th percentiles] otherwise. Mortality and hospitalization rate were compared between cases and controls using conditional logistic regression to take into account paired data. Conditional logistic regression models were used to identify factors associated with negative RT-PCR test. Step by step backward selection was applied. Predefined factors associated with negative RT-PCR testing at *P* values ≤0.2 by univariable analysis will then introduce in multiple logistic regressions with retaining of variable associated with P value ≤0.1(conservative approach). Homesher-Lemeshow test and visual inspection of residues were used to ensure the quality of the regression. Quantitative variable were dichotomized according to their median. Selection of collinear variable was performed according to their clinical relevance. Selection of model was based on Akaike information criterion (AIC) (10). Regarding importance of duration between symptoms onset and RT-PCR testing in previous literature, it was forced in all models. All statistical analyses were performed using SAS (Microsoft, Redmond, CA, USA).

Sample size

Regarding exploratory nature of our study, we did not set sample size but we targeted at least 50 patients and 50 controls (100 patients).

.

RESULTS

Between March 30, and June 22, 2020, 82 cases and 80 controls were included. Related to non-inclusion of matched controls, 2 cases patients were excluded from analysis. Patients were mainly male (66.25%), were 64.1±16.8 years old and were mainly admitted in ward (71.25%).

Of the 80 cases included, a chest radiography was performed for 26 patients (normal (N=1), ground-glass opacities (N=4), local patchy opacities (N=1), bilateral patchy opacities (N=12), interstitial abnormalities (N=7) and a chest CT scan was performed for 75 cases (normal (N=1), ground-glass opacities (N=69), interstitial abnormalities (N=4).

RT-PCR test was realized 6 [2.5-10.5] days after symptoms onset for cases and 5 [1.0-9.0] days for controls (P=0.2715). For 11 cases with subsequent positive RT-PCR test, it was performed 11.0 [9.0-16.0] after symptoms onset.

Final diagnosis of COVID-19 cases (N=80) were established on (multiple answers were allowed for each patient): subsequent oropharyngeal positive RT-PCR (N=9), subsequent expectoration positive RT-PCR (N=1), subsequent tracheal positive RT-PCR (N=4), chest CT scan (N=71), contagion from closed family member (N=13), returned from infected clusters (N=2), serology (N=2).

Clinical participant's characteristics for the cases and the controls are detailed in Table 1, and their biological characteristics in Table 2.

On univariable analysis, fatigue/malaise (P=0.0482), headache (P=0.0481), history of fever (P=0.0202), myalgia (0.0239) and elevation of hepatic enzymes (P=0.0239 for ALAT and

P=0.0239 for ASAT) were associated with lower risk of negative PCR test (OR<1);whereas, platelets upper than 207 per $10.^{3}.mm^{-3}$ (P=0.0015), white blood cells >6.95 per $10.^{3}.mm^{-3}$ (P=0.0003) and CRP>79.8 $mg.L^{-1}$ (P=0.279) were associated with higher risk of negative RT-PCR test (OR>1).

Because ASAT, ALAT were collinear of platelets count and white blood cells were collinear of CRP, they were not included in multivariable analysis. Result of multivariable analysis is depicted on Figure 1 with an AIC: 54.8 and BIC: 69.1.

Proportion of patients “Cases” and “controls” who received at least one treatment (Chloroquine, Corticosteroids, Lopinavir/ritonavir, Macrolids or Tocilizumab) did not differ (P=0.26) (Table 3). Mechanical ventilation was required for 10 (12.66%) cases and 14 (17.72%) controls, for duration of 21 [16-35] days for cases and 15 [5-21] days for controls.

Neither proportion of death at hospital discharge, nor duration of hospital length stay differed between patients “Cases” and “Controls” (respectively P=0.53 and P=0.79).

DISCUSSION

We found that patients with high elevation of CRP, high platelets count, expected high risk of false negative RT-PCR test, whereas patients with non-specific symptoms such as headache or fatigue/malaise expected lower risk. Duration between symptoms onset and time of RT-PCR testing was not associated with false negative result of RT-PCR test in our study. Finally, patients with false negative test did receive neither different treatments nor their expected different outcome according to proportion of patients requiring mechanical ventilation and mortality at hospital discharge.

Tree main conclusions can be drawn.

First, duration between symptoms onset and time to RT-PCR test was not associated with positivity. We think than such result can be explained by difficulties in the medical history examination especially in older patients (64±17 years) in our cohort as previously described for other disease (11). Additionally, frequent presence of delirium (up to 25%) in the geriatric patients can hypothesized duration reported (12).

Second, association between high level of CRP and higher risk of negative RT-PCR test is of interest because: 1) It is an argument for mortality associated with cytokine storm regardless of viral load (13) 2) It is problematic according to results of RECOVERY trial which indicates than corticosteroids is the only treatment proved effective to reduce mortality for patients with COVID-19 (14). Small proportion of our patients received corticosteroids but our study took place before evidence of beneficial effects of early short course of corticosteroids. Additional data suggests than corticosteroids benefit most to patients with level of CRP higher than 20 mg/dL (15) striking our results. In other part, RECOVERY did

not mandate positive RT-PCR to be included and randomized in the study (11% of the whole cohort). Interestingly, Hu et al found than headache was associated with intermittent negative COVID-19 RT-PCR status (16), highlighting our result about headache in our multivariable analysis.

Third, low rate of final diagnosis according to positive PCR test is also a concern. Some protocols advocated positive PCR test to include patients (17) and we can hypotheses than physician will be less prone to prescribe treatment to patients without positive PCR test. Global sensitivy of RT-PCR is describe as to 70% (18) but with major impact of duration between symptoms onset and day of RT-PCR testing: between 38% of false negative at day of symptoms onset to 20% at day 8 and then false negative rate which increase again (19). Long *et al*, found a positive rate of only 3.5% for patients first initial RT-PCR testing and subsequent retest for the next 7 days. Ai *et al*, found than chest CT has a high sensitivity for diagnosis of COVID-19 and may be considered as a primary tool for detection in epidemic area (20). Finally, strategy to perform several tests to document virologic proof of COVID-19 can be debated.

Our study took place during first epidemic wave in France and Belgium and was dedicated only to patients requiring hospitalization. It leads to high pre-test probability of COVD-19.We selected carefully patients hospitalized with several strong arguments for COVID-19 and final diagnosis of COVID-19 at hospital discharge.

Some limitations of our study must be highlighted.

First, negative RT-PCR test can be related to other disease. However, 45 (59.96%) of cases received negative others pathogens research during their hospital length stay and final diagnosis of COVID-19 was performed according to multimodal strategy including chest CT-

scans in 88.75% of case. Second, some issues could occurred during technical perform of RT-PCR but all RT-PCR were performed in hospitals with trained nurses and dedicated protocol to ensure high adherence to methods of RT-PCR realization. Third, our sample size is limited, but we choose to restrained inclusion of patients with robust arguments of COVID-19 according to others methods of diagnosis (especially chest CT-scans) with limited availability during epidemic wave in Europe. Last, we included patients for several centres with different RT-PCR detection kit. However, evidence suggests similar performance of available RT-PCR kits (21, 22).

CONCLUSIONS

Patients with first negative RT-PCR test for COVID-19 expected inflammatory markers even at median duration of 6 days after symptoms onset. Decision to perform or to withdraw special treatments such as corticosteroids for patients with COVID-19 cannot be done only on virologic isolation of SARS-CoV-2. Multimodal strategy for diagnosis including radiological findings and clinical history is mandatory for each patient suspected of COVID-19.

ACKNOWLEDGEMENT

We thank M. Rouaud, PharmD, for help during administrative process. We thank Mariana Ismael for Castor EDC (Amsterdam, The Netherlands) for technical support to design eCRF.

REFERENCES

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020;382(18):1708-20.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine.382(8):727-33.
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395(10229):1054-62.
4. Li D, Wang D, Dong J, Wang N, Huang H, Xu H, et al. False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases. Korean J Radiol.21(4):505-8.
5. Bai HX, Hsieh B. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. 2020;296(2):E46-e54.
6. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020;20(5):453-4.
7. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. 2020;581(7809):465-9.
8. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020:2020.02.11.20021493.
9. von Elm E, Altman DG, Egger M, Pocock SJ, GÃ¸tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453-7.
10. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19(6):716-23.
11. Ouellet GM, Geda M, Murphy TE, Tsang S, Tinetti ME, Chaudhry SI. Prehospital Delay in Older Adults with Acute Myocardial Infarction: The ComprehenSIVe

Evaluation of Risk Factors in Older Patients with Acute Myocardial Infarction Study. Journal of the American Geriatrics Society. 2017;65(11):2391-6.

12. Zerah L, Baudouin E, Pepin M, Mary M, Krypciak S, Bianco C, et al. Clinical Characteristics and Outcomes of 821 Older Patients with SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards. The journals of gerontology Series A, Biological sciences and medical sciences. 2020.
13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-4.
14. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. New England Journal of Medicine. 2020.
15. Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, et al. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. Journal of hospital medicine. 2020;15(8):489-93.
16. Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. The Science of the total environment. 2020;728:138812.
17. Maskin LP, Olarte GL, Palizas F, Jr., Velo AE, Lurbet MF, Bonelli I, et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):743.
18. Woloshin S, Patel N. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. 2020;383(6):e38.
19. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020;173(4):262-7.
20. Ai T, Yang Z. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. 2020;296(2):E32-e40.
21. Görzer I, Buchta C, Chiba P, Benka B, Camp JV, Holzmann H, et al. First results of a national external quality assessment scheme for the detection of SARS-CoV-2 genome sequences. Journal of Clinical Virology. 2020;129:104537.
22. Kapitula DS, Jiang Z, Jiang J, Zhu J, Chen X, Lin CQ. Performance; Quality Evaluation of Marketed COVID-19 RNA Detection Kits. medRxiv. 2020:2020.04.25.20080002.

Table 1 : Baseline characteristics

	Total N=160	**Case N=80**	**Control N=80**	**P value**
Matching characteristics				
Age, mean±SD	64.1±16.8	64.0±16.9	64.1±16.7	-
Gender Male, n (%)	106 (66.25%)	53 (66.25%)	53 (66.25%)	-
ICU admission, n (%)	46 (28.75%)	23 (28.75%)	23 (28.75%)	-
Non-matching characteristics				
BMI, median [IQR]	27.47 [24.45;30.81]	27.31 [24.46;29.09]	27.76 [23.57;31.30]	
Smoker, n (%)	23 (14.74%)	13 (16.88%)	10 (12.66%)	
Charlson score, median [IQR]	1 [0;3]	1 [0;2]	1 [0;3]	
Duration between onset symptoms and hospital admission, median [IQR]	7.00 [4.00;11.00]	7.00 [4.00;13.00]	7.00 [3.00;10.00]	0.1613
Locations countries traveled Belgium France	 22 (13.75%) 138 (86.25%)	 11 (13.75%) 69 (86.25%)	 11 (13.75%) 69 (86.25%)	
Duration between onset symptoms and ICU admission, median [IQR]	11. [7;14]	13 [7;15]	9 [7;13]	0.1203
Temperature, median [IQR]	37.7 [37.0;38.4]	37.5 [36.90;38.4]	38.0 [37.1;38.5]	0.1139
Heart rate (beats/minute), median [IQR]	87 [75;102]	89 [80;105]	86 [74;99]	0.0660
Respiratory rate (beats/minute), median [IQR]	25.00 [20;30]	24.00 [20;32]	25.00 [22;30]	0.7715
Systolic BP (mmHg), median [IQR]	132 [119;144]	130 [120;141]	136 [117.00;149]	0.4769
Diastolic BP (mmHg), median [IQR]	75 [66;84]	74 [65;82]	75 [67;84]	0.7439
Oxygen saturation (%), median [IQR]	95 [93;97]	94 [92;97]	95 [93;97]	0.9838
Oxygen saturation on Room_air Oxygen therapy	 101 (63.13%) 59 (36.88%)	 47 (58.75%) 33 (41.25%)	 54 (67.50%) 26 (32.50%)	0.2127
History of fever, n (%)	127 (80.38%)	57 (72.15%)	70 (88.61%)	0.0202
Dry cough, n (%)	94 (59.49%)	45 (56.96%)	49 (62.03%)	0.4665
Cough with bloody sputum, n (%)	31 (19.62%)	15 (18.99%)	16 (20.25%)	0.8055

Sore throat, n (%)	10 (7.19%)	7 (10.00%)	3 (4.35%)	0.1785
Rhinorrhoea, n (%)	19 (13.10%)	10 (13.89%)	9 (12.33%)	0.7877
Ear pain, n (%)	1 (0.68%)	0 (0.00%)	1 (1.37%)	0.9907
Wheezing, n (%)	8 (5.33%)	6 (7.79%)	2 (2.74%)	0.4235
Chest pain, n (%)	22 (14.57%)	13 (16.88%)	9 (12.16%)	0.3744
Myalgia, n (%)	40 (27.78%)	14 (19.72%)	26 (35.62%)	0.0239
Arthralgia, n (%)	7 (5.00%)	2 (2.86%)	5 (7.14%)	0.2734
Fatigue/Malaise, n (%)	87 (56.86%)	38 (50.00%)	49 (63.64%)	0.0482
Dyspnea, n (%)	107 (67.30%)	58 (73.42%)	49 (61.25%)	0.0823
Lower chest wall indrawing, n (%)	11 (7.53%)	5 (6.94%)	6 (8.11%)	0.4235
Headache, n (%)	22 (14.67%)	7 (9.21%)	15 (20.27%)	0.0481
Altered consciousness/confusion, n (%)	21 (13.91%)	9 (12.00%)	12 (15.79%)	0.3326
Abdominal pain, n (%)	23 (15.13%)	11 (14.10%)	12 (16.22%)	0.5943
Vomiting/Nausea, n (%)	25 (15.82%)	13 (16.46%)	12 (15.19%)	0.8273
Diarrhoea, n (%)	42 (26.92%)	19 (24.68%)	23 (29.11%)	0.5495
Skin ulcers, n (%)	1 (0.65%)	1 (1.32%)	0 (0.00%)	0.9907
Lymphadenopathy, n (%)	1 (0.71%)	1 (1.47%)	0 (0.00%)	0.9939
Bleeding/Haemorrhage, n (%)	3 (1.95%)	2 (2.63%)	1 (1.28%)	0.5714

Table 2 : Biological characteristics

	Total N=160	**Case N=80**	**Control N=80**	**P value**
Haemoglobin - hospital Admission (g/dL), median [IQR]	13.35 [12.00;14.60]	13.35 [11.95;14.55]	13.35 [12.20;14.60]	0.8618
WBC (10.3/mm3), median [IQR]	6.95 [5.23;9.60]	8.67 [6.30;11.30]	5.87 [4.80;7.70]	0.004
Lymphocyte (cells/microL) , median [IQR]	1010.0 670.00;1470.00]	1055.0 [750.00;1460.0 0]	950.0 650.00;1470.00]	0.3362
Neutrophil (cells/microL) , median [IQR]	5.02 [3.50;7.33]	4.67 [3.27;7.30]	5.64 [3.75;7.38]	0.6258
Haematocrit (%), median [IQR]	39.60 [36.30;43.00]	39.20 [36.10;42.70]	39.90 [37.00;43.00]	0.6156
Platelets (10.3/mm3), median [IQR]	207.50 [156.50;275.00]	244.00 [187.00;330.00]	179.00 [147.00;236.00]	0.0008
PT (seconds), median [IQR]	14.00 [12.90;15.40]	14.15 [13.35;15.45]	13.60 [12.60;15.40]	0.4734
INR, median [IQR]	1.08 [1.00;1.18]	1.08 [1.00;1.20]	1.09 [0.98;1.18]	0.5204
ALT/SGPT U/L, median [IQR]	34.00 25.00;53.00]	29.40 [21.00;46.00]	39.00 [31.50;59.00]	0.0239
Total Bilirubin (µmol/L), median [IQR]	9.00 [6.00;12.00]	8.78 [6.00;14.00]	9.00 [6.00;11.97]	0.4066
AST SGOT (U/L), median [IQR]	47.00 [32.00;70.00]	40.00 [26.80;66.00]	54.65 [36.85;77.50]	0.0239
Glucose (mmol/L), median [IQR]	6.31 [5.75;7.63]	6.50 [5.80;7.50]	6.30 [5.50;7.90]	0.4950
Blood Urea Nitrogen (mmol/L), median [IQR]	7.00 [4.70;11.42]	7.30 [5.10;11.00]	6.70 [4.30;12.10]	0.4334
Lactate (mmol/L), median [IQR]	1.30 [0.90;1.70]	1.30 [0.90;1.90]	1.20 [0.90;1.50]	0.3736
Creatininemia (µmol/L), median [IQR]	84.00 [67.00;104.00]	84.50 [68.00;104.00]	83.00 [66.00;104.00]	0.3474
Sodium (mEq/L) , median [IQR]	137.0 135.00;139.50]	136.0 [135.00;139.00]	137.0 [135.00;140.00]	0.8476
Potassium (mEq/L) , median [IQR]	4.10 [3.72;4.30]	4.10 [3.79;4.40]	4.00 [3.70;4.30]	0.5206
Procalcitonin (ng/mL) , median [IQR]	0.19 [0.08;0.49]	0.18 [0.11;0.28]	0.21 [0.08;0.89]	0.3763
CRP (mg/L) , median [IQR]	79.8 [40.0;179.0]	103.6 [42.0;214.0]	63.5 [36.6;131.0]	0.1466

Table 3: Treatments and outcomes

	Total N=160	**Case N=80**	**Control N=80**	**P value**
Lopinavir/Ritonavir, n (%)	17 (10.63%)	5 (6.25%)	12 (15.00%)	
Remsedivir, n (%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	
Hydroxychloroquine, n (%)	39 (24.53%)	19 (23.75%)	20 (25.32%)	
Macrolids, n (%)	70 (43.75%)	34 (42.50%)	36 (45.00%)	
Tocilizumab, n (%)	3 (1.88%)	1 (1.25%)	2 (2.50%)	
Al least one anti-viral, n (%)	62 (38.75%)	28 (35.00%)	34 (42.50%)	0.2606
Corticosteroids, n (%)	10 (6.25%)	6 (7.50%)	4 (5.00%)	
Outcome at hospital discharge Discharge alive Death	 135 (85.44%) 23 (14.56%)	 68 (86.08%) 11 (13.92%)	 67 (84.81%) 12 (15.19%)	0.7964
Duration between hospital admission and death, median [IQR]	9.00 [5.00;17.00]	10.00 [6.00;23.00]	6.50 [4.50;16.50]	0.5357
Duration between hospital admission and hospital discharge, median [IQR]	8.00 [4.00;15.00]	8.00 [4.50;16.00]	8.50 [4.00;15.00]	
Mechanical ventilation, n (%)	24 (15.19%)	10 (12.66%)	14 (17.72%)	0.1772
Duration of mechanical ventilation, median [IQR]	18.00 [11.00;27.00]	21.50 [16.00;35.00]	15.50 [5.00;21.00]	
ARDS, n (%)	29 (18.71%)	14 (18.42%)	15 (18.99%)	0.5943
Grade of ARDS, n (%) Mild Moderate Severe	 2 (6.90%) 9 (31.03%) 18 (62.07%)	 2 (14.29%) 3 (21.43%) 9 (64.29%)	 0 (0.00%) 6 (40.00%) 9 (60.00%)	
Duration between hospital admission and hospital discharge or death, median [IQR]	8.00 [5.00;16.00]	8.00 [5.00;17.00]	8.00 [4.00;16.00]	

Figure 1: Forrest plot of multivariable analysis of factors associated with first negative RT-PCR COVID-19 testing